(Q47903730)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28371827%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

title

Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28371827%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

1 reference

1 reference

Tiffany R Hodges

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28371827%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

Martina Ott

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28371827%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

Joanne Xiu

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28371827%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

Zoran Gatalica

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28371827%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

Jeff Swensen

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28371827%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

Shouhao Zhou

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28371827%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

Jason T Huse

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28371827%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

John de Groot

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28371827%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

Shulin Li

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28371827%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

Willem W Overwijk

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28371827%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

David Spetzler

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28371827%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

Amy B Heimberger

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28371827%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

publication date

1 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28371827%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28371827%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

volume

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28371827%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28371827%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

page(s)

1047-1057

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28371827%20AND%20SRC:MED&resulttype=core&format=json

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

15 March 2020

cites work

1 reference

12 December 2020

Mutation of the PIK3CA gene in ovarian and breast cancer

1 reference

12 December 2020

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

1 reference

12 December 2020

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

1 reference

12 December 2020

Exomics and immunogenics: Bridging mutational load and immune checkpoints efficacy

1 reference

12 December 2020

Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade

1 reference

12 December 2020

The expression of mismatch repair proteins MLH1, MSH2 and MSH6 correlates with the Ki67 proliferation index and survival in patients with recurrent glioblastoma

1 reference

12 December 2020

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

1 reference

12 December 2020

A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy.

1 reference

12 December 2020

MiR-422a acts as a tumor suppressor in glioblastoma by targeting PIK3CA.

1 reference

12 December 2020

Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency.

1 reference

12 December 2020

Biomarkers in cancer immunotherapy

1 reference

12 December 2020

Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers

1 reference

12 December 2020

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

1 reference

12 December 2020

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

1 reference

12 December 2020

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

1 reference

12 December 2020

Genetic basis for clinical response to CTLA-4 blockade in melanoma

1 reference

12 December 2020

Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type

1 reference

12 December 2020

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

1 reference

12 December 2020

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

1 reference

12 December 2020

Somatic POLE mutations cause an ultramutated giant cell high-grade glioma subtype with better prognosis

1 reference

12 December 2020

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

1 reference

12 December 2020

Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1

1 reference

12 December 2020

High frequency of mutations of the PIK3CA gene in human cancers

1 reference

12 December 2020

MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance.

1 reference

12 December 2020

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

1 reference

12 December 2020

Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial

1 reference

12 December 2020

Burden of Nonsynonymous Mutations among TCGA Cancers and Candidate Immune Checkpoint Inhibitor Responses

1 reference

12 December 2020

The somatic POLE P286R mutation defines a unique subclass of colorectal cancer featuring hypermutation, representing a potential genomic biomarker for immunotherapy.

1 reference

12 December 2020

Next-generation sequencing identifies high frequency of mutations in potentially clinically actionable genes in sebaceous carcinoma.

1 reference

12 December 2020

PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients

1 reference

12 December 2020

Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology

1 reference

12 December 2020

Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies

1 reference

12 December 2020

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

1 reference

12 December 2020

Inactivation of the ATMIN/ATM pathway protects against glioblastoma formation

1 reference

12 December 2020

Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment

1 reference

12 December 2020

Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels

1 reference

12 December 2020

Identifiers

DOI

10.1093/NEUONC/NOX026

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28371827%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28371827%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

1 reference